Evidence map›Paper›PMID 39936977›Full record

ArticleCells2025

Monensin Inhibits Triple-Negative Breast Cancer in Mice by a Na

Simone Fiorilla, Francesco Tasso, Nausicaa Clemente, Tommaso Trisciuoglio, Renzo Boldorini, Rita Carini

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Monensin suppresses EMT-driven cancer cell motility by inducing Golgi pH-dependent exocytosis of GOLIM4.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Simone FiorillaDepartment of Health Science, Università del Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy.ORCID 0000-0003-3680-4919
Francesco TassoDepartment of Health Science, Università del Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy.ORCID 0000-0002-5563-0718
Nausicaa ClementeDepartment of Health Science, Università del Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy.ORCID 0000-0002-9860-0148
Tommaso TrisciuoglioDepartment of Health Science, Università del Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy.
Renzo BoldoriniDepartment of Health Science, Università del Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy.
Rita CariniDepartment of Health Science, Università del Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy.ORCID 0000-0001-8159-2738

Funding

Italian Association for Cancer Research IG-2020-24351
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype, defined by its limited therapeutic options and poor outcomes. This study investigated the therapeutic potential of targeting Na

Indexed as

Cytostatic AgentsMonensinSodiumTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceMice, Inbred BALB CCytostatic AgentsMonensinSodiumanticancer treatmentcancer cell deathNa+ ionophores

Identifiers

PMID39936977
PMCPMC11817484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.